Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension (PH), a disease associated with abnormally high pressure in the blood vessels of the lungs, caused by the formation of blood clots. CTEPH also can be referred to as group 4 PH, the World Health Organization classification that…
Search results for:
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension caused by blood clots obstructing the pulmonary arteries. Unlike other forms, CTEPH can often be treated or cured with surgery. Diagnosis requires specific imaging tests, such as V/Q scans or angiograms.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Social Clips
Thromboembolic Pulmonary Hypertension
“In this video, from the Texas Heart Institute, meet Deborah Meyers, MD, and her patient Trasetta Terry, a retired pharmacist who tells us about her experience with thromboembolic pulmonary hypertension.” Keep up to date on all the latest PH news here: https://bit.ly/20LXxHN…
Quality of life is an important measure of patient health and treatment effectiveness, but often overlooked in people with chronic thromboembolic pulmonary hypertension (CTEPH). A review of such measurements in this patient group found plenty of room for improvement both in tools selected and their use — and called for more research on the…
New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal by Dr. Diana Zabini, part…
The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) has been identified as one of the major causes of acute pulmonary hypertension (PH). This condition is characterized by a progressively dangerous accumulation of blood clots within pulmonary vasculature, which leads to PH and can eventually cause right-sided heart failure. It…
People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…
People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…
Social Clips
CTEPH: What You Need to Know
https://www.youtube.com/watch?v=W2YLo6U1uFU Pulmonary hypertension (PH) is a rare lung disease that refers to an increase in blood pressure in the pulmonary arteries. Unfortunately, there is still no known cure available to end PH, but research has been evolving and doctors and scientists have been discovering some new ways to approach this…
In this video from PHA Canada, meet Dr. Sanjay Mehta. Dr. Mehta is a CTEPH-treating doctor and in this clip shared in 2014, he discusses some important information on CTEPH and pulmonary hypertension. Read the latest updates on pulmonary hypertension: https://bit.ly/1K4oewk…
https://vimeo.com/184579437 In this video from Elsevier Pharma Solutions, Professor Marc Humbert discusses the diagnostic processes for pulmonary hypertension and chronic thromboembolic pulmonary hypertension (CTEPH)—which is a curable form of the disease. RELATED: A study find international diagnosis and management of CTEPH is inadequate. Prof. Hubert explains that CTEPH is…
Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH) in a Phase 3 clinical trial, although its use did not significantly affect measures of physical abilities. Full trial results are in “Selexipag for the treatment of…